New No-Injection Weight-Loss Pill Helps Cut Body Weight by 12 Percent

Phase 2 clinical trials of a new oral medication called aleniglipron have demonstrated significant weight reduction in adults struggling with obesity, according to data published in Nature Medicine. Participants taking the daily tablet lost up to 12% of their body weight over a 36-week period. While aleniglipron mimics the glucagon-like peptide-1 (GLP-1) hormone—which suppresses appetite and extends satiety—it differs fundamentally from popular injectable treatments like semaglutide (Ozempic, Wegovy). Chemical Structure and Administration Unlike peptide-based drugs that require complex biological manufacturing and strict cold-chain storage, aleniglipron is a "small molecule" synthesized chemically. This allows the medication to be administered as a standard tablet regardless of food intake.